8-K: Y-mAbs Reports Q4 2024 Financial Results: Revenue Up, Focus Shifts to Radiopharmaceuticals

Y-mAbs reports increased revenue for Q4 2024 and announces a strategic realignment to focus on radiopharmaceuticals and DANYELZA commercial growth.

Summary

• Y-mAbs Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Total revenues for Q4 2024 were $26.5 million, a 13% increase compared to $23.4 million in Q4 2023.
• Full-year 2024 total revenues reached $87.7 million, a 3% increase from $84.8 million in 2023.
• The company's cash and cash equivalents stood at $67.2 million as of December 31, 2024.
• Y-mAbs established two business units in January 2025, focusing on Radiopharmaceuticals and DANYELZA.
• Full year 2025 revenue is expected to be between $75 million and $90 million.
• Total annual cash investment for 2024 was $11.4 million.
• The company anticipates total operating costs and expenses between $129 million and $134 million for 2025.
• The company expects cash and cash equivalents to be sufficient to fund operations into 2027.
• First quarter 2025 revenue is expected to be between $18 million and $21 million.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue increased, the company still reported a net loss. The strategic realignment and focus on radiopharmaceuticals are viewed positively, but the challenges in the U.S. market for DANYELZA temper the overall outlook.

Positives

• Total revenues increased by 13% in Q4 2024 and 3% for the full year 2024.
• The company secured an exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan, including a $2.0 million upfront payment.
• Cash investment for 2024 was lower than the initially projected guidance.
• The company's cash reserves are expected to sustain operations into 2027.
• International DANYELZA net product revenues increased by 78% for the quarter and 16% for the year ended December 31, 2024.
• Y-mAbs received notification of the accepted patent extension for DANYELZA, US 9,315,585, through February 2034.

Negatives

• U.S. DANYELZA net product revenues decreased by 12% for the quarter and 3% for the year ended December 31, 2024, due to an unfavorable price mix.
• The company reported a net loss of $6.8 million for Q4 2024, compared to a net loss of $1.0 million for Q4 2023.
• The company reported a net loss of $29.7 million for the year ended December 31, 2024, as compared to net loss of $21.4 million for the year ended December 31, 2023.
• Gross profit decreased due to the unfavorable price mix in connection with increased net product revenue from Eastern Asia, which generally has lower gross margins.

Risks

• The company's financial condition requires careful management of cash resources.
• The success of the business realignment is not guaranteed.
• Delays or failures in regulatory submissions or approvals could negatively impact the company.
• Market acceptance of the company's products is subject to uncertainty.
• The company is dependent on third parties for clinical testing and product manufacturing.
• Macroeconomic conditions, including inflation and increased interest rates, could pose challenges.

Future Outlook

Management anticipates total revenues between $75 million and $90 million for the full year 2025 and expects cash and cash equivalents to be sufficient to fund operations into 2027.

Management Comments

• We delivered on the strategic priorities we set out to achieve in 2024 across our business, said Michael Rossi, President and Chief Executive Officer.
• With our business realignment announced at the beginning of 2025, we expect to be in position to enhance our ability to execute on our business goals to drive future growth with DANYELZA while accelerating the preclinical and clinical advancement of our SADA PRIT platform and programs.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment. The realignment reflects a strategic shift to capitalize on the potential of its Radiopharmaceutical platform while sustaining DANYELZA's commercial growth.

Comparison to Industry Standards

• It is difficult to compare Y-mAbs directly to industry standards without knowing the specific neuroblastoma treatment market size and growth rate.
• Companies like United Therapeutics, which also focuses on rare diseases, could be a benchmark for commercialization strategies.
• The SADA PRIT platform competes with other targeted radiotherapies being developed by companies like Novartis with Pluvicto.
• The $2 million upfront payment from Nobelpharma is a standard deal structure for licensing agreements in the pharmaceutical industry, but the total potential value of $33 million is relatively small compared to deals for more common indications.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and strategic decisions.
• Employees may be affected by the business realignment and any associated personnel changes.
• Patients with neuroblastoma may benefit from the continued development and commercialization of DANYELZA and other therapies.
• The agreement with Nobelpharma could expand access to DANYELZA for patients in Japan.

Next Steps

• The company plans to continue commercializing DANYELZA and advancing its SADA PRIT platform.
• Y-mAbs will provide a complete data readout from Part A of its GD2-SADA Phase 1 trial in the second quarter of this year.
• The company will focus on penetrating high-volume centers and reaching more patients with high-risk relapsed/refractory neuroblastoma.

Key Dates